Salzburg Therapeutics^®

SALZBURG THERAPEUTICS is an innovative drug development company that is developing unique Cytotoxamer^® and Genotoxamer^® products for cancer treatment.    Our technology provides an innovative solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.  

The Cytotoxamer^®  approach simultaneously improves efficacy and reduces the toxicities associated with traditional chemotherapy.  The end-result is a longer and a higher quality of life for cancer patients.

The initial focus for product development at Salzburg Therapeutics is a Cytotoxamer^® for the treatment of prostate cancer.

Salzburg Therapeutics is also developing FdUMP[10] and other FdUMP polymers for treatment of acute myelogenous leukemia.

 Management Team

William Gmeiner, Ph.D., MBA - CSO

Stan Mandel, Ph.D., MBA - CEO

Scientific Advisory Board

Bayard Powell, MD Chief, Hem/Onc WFSM Comprehensive Cancer Center

Edward Chu, M.D. Deputy Director      Yale Cancer Center

Yong Chen, Ph.D., Professor, Department of Cancer Biology, Wake Forest University

Waldemar Debinski, M.D., Ph.D. Director, WFUSM Brain Tumor Center of Excellence

Frits Peters, Ph.D., Professor, VU University, Amsterdam 

News

January 2012: Bayard Powell, MD joins Salzburg Scientific advisory board.  Dr. Powell is an expert in hematological malignancies, reflecting the high priority of leukemias for product development.

November 2010: Salzburg Therapeutics receives grant from Healthcare bill as mentioned in the Triad business journal.

May 2009: Salzburg Therapeutics featured in Triad Business Journal article highlighting innovative cancer-focused therapeutic companies
 

April 2009: Salzburg Therapeutics announces completion of a licensing deal with UneMed for the commercial development of oligonucleotides containing FdUMP

October 2008: Salzburg Therapeutics is featured in a Piedmont Triad Business Journal news feature. 

May 2008: Salzburg Therapeutics is announced as a Grand Prize Winner in the PTEN Growth Accelerator Program Competition. 

April 2008: Salzburg Therapeutics is pleased to announce Waldemar Debinski, M.D., Ph.D., Director of the WFUSM Brain Tumor Center of Excellence and Godefridus J. (Frits) Peters, Ph.D., Professor of Medical Oncology at VU University Medical Center, Amsterdam have joined our scientific advisory board. 

March 2008: Salzburg Therapeutics is pleased to announce that Edward Chu, M.D., Deputy Director of the Yale Cancer Center, will serve on our scientific advisory board. 

January 2008: Salzburg Therapeutics joins the WFU Demon Incubator